Difenoconazole; Pesticide Tolerances, 8447-8454 [2020-02241]
Download as PDF
8447
Federal Register / Vol. 85, No. 31 / Friday, February 14, 2020 / Rules and Regulations
TABLE 1 TO 180.910
Inert ingredients
Limits
*
*
*
*
*
Ethylenebis(oxyethylene) bis[3-(5-tert-butyl-4-hydroxy-m-tolyl) propionate] (CAS Reg. No. 36443–68–
2).
*
1% by weight ........
*
*
*
[FR Doc. 2020–02043 Filed 2–13–20; 8:45 am]
BILLING CODE 6560–50–P
ENVIRONMENTAL PROTECTION
AGENCY
40 CFR Part 180
[EPA–HQ–OPP–2018–0718 and EPA–HQ–
OPP–2019–0076; FRL–10002–06]
Difenoconazole; Pesticide Tolerances
Environmental Protection
Agency (EPA).
ACTION: Final rule.
AGENCY:
This regulation establishes
tolerances for residues of
difenoconazole in or on vegetable, root,
subgroup 1A, except ginseng; vegetable,
leaves of root and tuber, group 2; and
tea, dried. In addition, this regulation
amends the tolerances for residues of
difenoconazole in or ginseng; cattle,
liver; goat, liver; horse, liver; and sheep,
liver. Syngenta Crop Protection, LLC
requested these tolerances under the
Federal Food, Drug, and Cosmetic Act
(FFDCA).
DATES: This regulation is effective
February 14, 2020. Objections and
requests for hearings must be received
on or before April 14, 2020, and must
be filed in accordance with the
instructions provided in 40 CFR part
178 (see also Unit I.C. of the
SUPPLEMENTARY INFORMATION).
ADDRESSES: The docket for this action,
identified by docket identification (ID)
number EPA–HQ–OPP–2018–0718 and
EPA–HQ–OPP–2019–0076, is available
at https://www.regulations.gov or at the
Office of Pesticide Programs Regulatory
Public Docket (OPP Docket) in the
Environmental Protection Agency
Docket Center (EPA/DC), West William
Jefferson Clinton Bldg., Rm. 3334, 1301
Constitution Ave. NW, Washington, DC
20460–0001. The Public Reading Room
is open from 8:30 a.m. to 4:30 p.m.,
Monday through Friday, excluding legal
holidays. The telephone number for the
Public Reading Room is (202) 566–1744,
and the telephone number for the OPP
Docket is (703) 305–5805. Please review
the visitor instructions and additional
khammond on DSKJM1Z7X2PROD with RULES
SUMMARY:
VerDate Sep<11>2014
17:46 Feb 13, 2020
Jkt 250001
*
*
information about the docket available
at https://www.epa.gov/dockets.
FOR FURTHER INFORMATION CONTACT:
Michael Goodis, Registration Division
(7505P), Office of Pesticide Programs,
Environmental Protection Agency, 1200
Pennsylvania Ave. NW, Washington, DC
20460–0001; main telephone number:
(703) 305–7090; email address:
RDFRNotices@epa.gov.
SUPPLEMENTARY INFORMATION:
I. General Information
A. Does this action apply to me?
You may be potentially affected by
this action if you are an agricultural
producer, food manufacturer, or
pesticide manufacturer. The following
list of North American Industrial
Classification System (NAICS) codes is
not intended to be exhaustive, but rather
provides a guide to help readers
determine whether this document
applies to them. Potentially affected
entities may include:
• Crop production (NAICS code 111)
• Animal production (NAICS code
112)
• Food manufacturing (NAICS code
311)
• Pesticide manufacturing (NAICS
code 32532)
B. How can I get electronic access to
other related information?
You may access a frequently updated
electronic version of EPA’s tolerance
regulations at 40 CFR part 180 through
the Government Publishing Office’s eCFR site at https://www.ecfr.gov/cgi-bin/
text-idx?&c=ecfr&tpl=/ecfrbrowse/
Title40/40tab_02.tpl.
C. How can I file an objection or hearing
request?
Under FFDCA section 408(g), 21
U.S.C. 346a, any person may file an
objection to any aspect of this regulation
and may also request a hearing on those
objections. You must file your objection
or request a hearing on this regulation
in accordance with the instructions
provided in 40 CFR part 178. To ensure
proper receipt by EPA, you must
identify docket ID number EPA–HQ–
OPP–2018–0718 and EPA–HQ–OPP–
2019–0076 in the subject line on the
PO 00000
Frm 00075
Fmt 4700
Sfmt 4700
Uses
*
Stabilizer.
*
*
first page of your submission. All
objections and requests for a hearing
must be in writing, and must be
received by the Hearing Clerk on or
before April 14, 2020. Addresses for
mail and hand delivery of objections
and hearing requests are provided in 40
CFR 178.25(b).
In addition to filing an objection or
hearing request with the Hearing Clerk
as described in 40 CFR part 178, please
submit a copy of the filing (excluding
any Confidential Business Information
(CBI)) for inclusion in the public docket.
Information not marked confidential
pursuant to 40 CFR part 2 may be
disclosed publicly by EPA without prior
notice. Submit the non-CBI copy of your
objection or hearing request, identified
by docket ID number EPA–HQ–OPP–
2018–0718 and EPA–HQ–OPP–2019–
0076, by one of the following methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the online
instructions for submitting comments.
Do not submit electronically any
information you consider to be CBI or
other information whose disclosure is
restricted by statute.
• Mail: OPP Docket, Environmental
Protection Agency Docket Center (EPA/
DC), (28221T), 1200 Pennsylvania Ave.
NW, Washington, DC 20460–0001.
• Hand Delivery: To make special
arrangements for hand delivery or
delivery of boxed information, please
follow the instructions at https://
www.epa.gov/dockets/contacts.html.
Additional instructions on
commenting or visiting the docket,
along with more information about
dockets generally, is available at https://
www.epa.gov/dockets.
II. Summary of Petitioned-For
Tolerance
In the Federal Register of June 7, 2019
(84 FR 26630) (FRL–9993–93) and in the
Federal Register of May 9, 2019 (84 FR
20320) (FRL–9992–36), EPA issued
documents pursuant to FFDCA section
408(d)(3), 21 U.S.C. 346a(d)(3),
announcing the filing of pesticide
petitions (PP 8F8695 and 8E8728,
respectively) by Syngenta Crop
Protection, LLC, P.O. Box 18300,
Greensboro, NC 27419. Pesticide
E:\FR\FM\14FER1.SGM
14FER1
8448
Federal Register / Vol. 85, No. 31 / Friday, February 14, 2020 / Rules and Regulations
petition 8F8695 requested that 40 CFR
180.475 be amended by establishing
tolerances for residues of the fungicide
difenoconazole in or on root vegetable
crop subgroup 1A at 0.60 parts per
million (ppm) and leaves of root and
tuber vegetables crop group 2 at 8.0
ppm; PP 8E8728 requested the
establishment of a tolerance for residues
of difenoconazole in or on tea at 30
ppm. Those documents referenced
summaries of the petitions prepared by
Syngenta Crop Protection, LLC, the
registrant, which are available in their
respective dockets, https://
www.regulations.gov. One comment was
received on EPA’s May 9, 2019 notice of
filing in docket number EPA–HQ–OPP–
2019–0076. EPA’s response to this
comment is discussed in Unit IV.C.
Based upon review of the data
supporting the petition, EPA is
establishing tolerances that vary from
what the petitioner requested as
permitted by FFDCA section
408(d)(4)(A)(i). These differences are
explained in Unit IV.D.
khammond on DSKJM1Z7X2PROD with RULES
III. Aggregate Risk Assessment and
Determination of Safety
Section 408(b)(2)(A)(i) of FFDCA
allows EPA to establish a tolerance (the
legal limit for a pesticide chemical
residue in or on a food) only if EPA
determines that the tolerance is ‘‘safe.’’
Section 408(b)(2)(A)(ii) of FFDCA
defines ‘‘safe’’ to mean that ‘‘there is a
reasonable certainty that no harm will
result from aggregate exposure to the
pesticide chemical residue, including
all anticipated dietary exposures and all
other exposures for which there is
reliable information.’’ This includes
exposure through drinking water and in
residential settings, but does not include
occupational exposure. Section
408(b)(2)(C) of FFDCA requires EPA to
give special consideration to exposure
of infants and children to the pesticide
chemical residue in establishing a
tolerance and to ‘‘ensure that there is a
reasonable certainty that no harm will
result to infants and children from
aggregate exposure to the pesticide
chemical residue. . . .’’
Consistent with FFDCA section
408(b)(2)(D), and the factors specified in
FFDCA section 408(b)(2)(D), EPA has
reviewed the available scientific data
and other relevant information in
support of this action. EPA has
sufficient data to assess the hazards of
and to make a determination on
aggregate exposure for difenoconazole
including exposure resulting from the
tolerances established by this action.
EPA’s assessment of exposures and risks
associated with difenoconazole follows.
VerDate Sep<11>2014
17:46 Feb 13, 2020
Jkt 250001
A. Toxicological Profile
EPA has evaluated the available
toxicity data and considered its validity,
completeness, and reliability as well as
the relationship of the results of the
studies to human risk. EPA has also
considered available information
concerning the variability of the
sensitivities of major identifiable
subgroups of consumers, including
infants and children.
Subchronic and chronic toxicity
studies with difenoconazole in mice and
rats showed decreased body weights
and effects on the liver (e.g.,
hepatocellular hypertrophy, liver
necrosis, fatty changes in the liver). No
systemic toxicity was observed at the
limit dose in a rat dermal toxicity study.
Difenoconazole exhibits low acute
toxicity by the oral, dermal and
inhalation routes of exposure. It is not
an eye or skin irritant and is not a
sensitizer.
Acute and subchronic neurotoxicity
studies showed evidence of mild
neurotoxic effects. However, the
selected endpoints of toxicity for risk
assessment are protective of any
potential neurotoxicity.
The available toxicity studies
indicated no increased susceptibility of
rats or rabbits from in utero or postnatal
exposure to difenoconazole. In prenatal
developmental toxicity studies in rats
and rabbits and in the 2-generation
reproduction study in rats, fetal and
offspring toxicity, when observed,
occurred at equivalent or higher doses
than in the maternal and parental
animals. In a rat developmental toxicity
study, developmental effects were
observed at doses higher than those
which caused maternal toxicity.
Developmental effects in the rat
included increased incidence of
ossification of the thoracic vertebrae and
thyroid, decreased number of sternal
centers of ossification, increased
number of ribs and thoracic vertebrae,
and decreased number of lumbar
vertebrae. In the rabbit study,
developmental effects (increases in postimplantation loss and resorptions and
decreases in fetal body weight) were
also seen at maternally toxic (decreased
body weight gain and food
consumption) doses. Since the
developmental effects are more severe
than the maternal effects, qualitative
susceptibility is indicated in the rabbit
developmental study; however, the
selected POD is protective of this effect.
In the 2-generation reproduction study
in rats, toxicity to the fetuses and
offspring, when observed, occurred at
equivalent or higher doses than in the
maternal and parental animals.
PO 00000
Frm 00076
Fmt 4700
Sfmt 4700
Although there is some evidence that
difenoconazole affects antibody levels at
doses that cause systemic toxicity, there
are no indications in the available
studies that organs associated with
immune function, such as the thymus
and spleen, are affected by
difenoconazole. Difenoconazole is not
mutagenic or genotoxic, and no
evidence of carcinogenicity was seen in
rats. Evidence for carcinogenicity was
seen in mice as induction of liver
tumors at doses which were considered
to be excessively high for
carcinogenicity testing. Difenoconazole
has been classified as ‘‘Suggestive
Evidence of Carcinogenic Potential’’
based on liver tumors observed in mice.
EPA has concluded that the chronic
point of departure (POD) for assessing
chronic risk will be protective of any
cancer effects for the following reasons:
(1) Tumors were seen in only one
species; (2) carcinoma tumors were
observed only at the two highest doses
in the mouse carcinogenicity study; (3)
benign tumors and necrosis were
observed at the mid-dose; (4) the
absence of tumors at the study’s lower
doses; (5) the absence of genotoxic or
mutagenic effects. The cRfD is well
below the no-observed- adverse-effectlevel (NOAEL) of the mouse
carcinogenicity study, at which no
effects on the biological endpoints
relevant to tumor development (i.e.,
hepatocellular hypertrophy, liver
necrosis, fatty changes in the liver and
bile stasis) were seen. As a result, EPA
has concluded that a nonlinear RfD
approach is appropriate for assessing
cancer risk to difenoconazole and a
separate quantitative cancer exposure
assessment is unnecessary.
Specific information on the studies
received and the nature of the adverse
effects caused by difenoconazole as well
as the no-observed-adverse-effect-level
(NOAEL) and the lowest-observedadverse-effect-level (LOAEL) from the
toxicity studies can be found at https://
www.regulations.gov in document
‘‘Difenoconazole. Human Health Risk
Assessment for Proposed New Foliar
Uses on All Members of Vegetable, Root,
Subgroup 1A and Vegetable, Leaves of
Root and Tuber, Group 2 and
Establishment of a Tolerance with No
U.S. Registration in/on Imported Tea’’
in docket ID number EPA–HQ–OPP–
2018–0718.
B. Toxicological Points of Departure/
Levels of Concern
Once a pesticide’s toxicological
profile is determined, EPA identifies
toxicological POD and levels of concern
to use in evaluating the risk posed by
human exposure to the pesticide. For
E:\FR\FM\14FER1.SGM
14FER1
Federal Register / Vol. 85, No. 31 / Friday, February 14, 2020 / Rules and Regulations
hazards that have a threshold below
which there is no appreciable risk, the
toxicological POD is used as the basis
for derivation of reference values for
risk assessment. PODs are developed
based on a careful analysis of the doses
in each toxicological study to determine
the NOAEL and the LOAEL.
Uncertainty/safety factors are used in
conjunction with the POD to calculate a
safe exposure level—generally referred
to as a population-adjusted dose (PAD)
or a RfD—and a safe margin of exposure
(MOE). For non-threshold risks, the
Agency assumes that any amount of
exposure will lead to some degree of
risk. Thus, the Agency estimates risk in
terms of the probability of an occurrence
of the adverse effect expected in a
lifetime. For more information on the
general principles EPA uses in risk
characterization and a complete
8449
description of the risk assessment
process, see https://www2.epa.gov/
pesticide-science-and-assessingpesticide-risks/assessing-human-healthrisk-pesticides.
A summary of the toxicological
endpoints for difenoconazole used for
human risk assessment is shown in
Table 1 of this unit.
TABLE 1—SUMMARY OF TOXICOLOGICAL DOSES AND ENDPOINTS FOR DIFENOCONAZOLE FOR USE IN HUMAN HEALTH
RISK ASSESSMENT
Point of departure
and uncertainty/
safety factors
RfD, PAD, LOC for
risk assessment
Study and toxicological effects
Acute dietary (All populations) ..
NOAEL = 25 mg/kg/
day
UFA = 10x
UFH = 10x
FQPA SF = 1x
Acute RfD = 0.25
mg/kg/day.
aPAD = 0.25 mg/kg/
day
Acute Neurotoxicity Study in Rats.
LOAEL = 200 mg/kg/day in males based on reduced fore-limb
grip strength in males on Day 1 and increased motor activity
on Day 1.
Chronic dietary (All populations)
NOAEL= 0.96 mg/
kg/day
UFA = 10x
UFH = 10x
FQPA SF = 1x
Chronic RfD = 0.01
mg/kg/day.
cPAD = 0.01 mg/kg/
day.
Combined Chronic Toxicity/Carcinogenicity (rat, dietary).
LOAEL = 24.1/32.8 mg/kg/day (male/female) based on cumulative decreases in body-weight gains.
Oral short-term (1 to 30 days) ..
NOAEL= 1.25 mg/
kg/day
UFA = 10x
UFH = 10x
FQPA SF = 1x
Residential LOC for
MOE = <100.
Reproduction and Fertility Study (rat dietary).
Parental/Offspring LOAEL = 12.5 mg/kg/day based on decreased pup weight in in males on Day 21 and reduction in
body weight gain of F0 females prior to mating, gestation and
lactation.
Dermal short-term (1 to 30
days) and intermediate-term
(1 to 6 months).
NOAEL = 1.25 mg/
kg/day (dermal absorption factor =
6%)
UFA = 10x
UFH = 10x
FQPA SF = 1x
LOC for MOE =
<100.
Reproduction and Fertility Study (rat, dietary).
Parental/Offspring LOAEL = 12.5 mg/kg/day based on decreased pup weight in males on Day 21 and reduction in
body weight gain of F0 females prior to mating, gestation and
lactation.
Inhalation short-term (1 to 30
days) and intermediate-term
(1 to 6 months).
* Inhalation and oral absorption
assumed equivalent.
NOAEL= 1.25 mg/
kg/day
UFA = 10x
UFH = 10x
FQPA SF = 1x
LOC for MOE =
<100.
Reproduction and Fertility Study (rat, dietary).
Parental/Offspring LOAEL = 12.5 mg/kg/day based on decreased pup weight in males on Day 21 and reduction in
body weight gain of F0 females prior to mating, gestation and
lactation.
Cancer (Oral, dermal, inhalation).
Difenoconazole is classified ‘‘Suggestive Evidence of Carcinogenic Potential’’. Quantification of cancer risk is
not required. The RfD would address the concern for chronic toxicity, including carcinogenicity, likely to result
from exposure to difenoconazole.
Exposure scenario
khammond on DSKJM1Z7X2PROD with RULES
FQPA SF = Food Quality Protection Act Safety Factor. LOAEL = lowest-observed-adverse-effect-level. LOC = level of concern. mg/kg/day =
milligram/kilogram/day. MOE = margin of exposure. NOAEL = no-observed-adverse-effect-level. PAD = population adjusted dose (a = acute, c =
chronic). RfD = reference dose. UF = uncertainty factor. UFA = extrapolation from animal to human (interspecies). UFH = potential variation in
sensitivity among members of the human population (intraspecies).
C. Exposure Assessment
1. Dietary exposure from food and
feed uses. In evaluating dietary
exposure to difenoconazole, EPA
considered exposure under the
petitioned-for tolerances as well as all
existing difenoconazole tolerances in 40
CFR 180.475. EPA assessed dietary
exposures from difenoconazole in food
as follows:
i. Acute exposure. Quantitative acute
dietary exposure and risk assessments
are performed for a food-use pesticide,
VerDate Sep<11>2014
17:46 Feb 13, 2020
Jkt 250001
if a toxicological study has indicated the
possibility of an effect of concern
occurring as a result of a 1-day or single
exposure. Such effects were identified
for difenoconazole. In estimating acute
dietary exposure, EPA used food
consumption information from the
United States Department of Agriculture
(USDA) National Health and Nutrition
Examination Survey, What We Eat in
America, (NHANES/WWEIA) 2003 to
2008. As to residue levels in food, EPA
assumed tolerance-level residues, 100
PO 00000
Frm 00077
Fmt 4700
Sfmt 4700
percent crop treated (PCT), and
available empirical or default processing
factors.
ii. Chronic exposure. In conducting
the chronic dietary exposure assessment
EPA used the food consumption data
from the USDA NHANES/WWEIA 2003
to 2008. As to residue levels in food,
EPA used tolerance-level residues for
some commodities, average field trial
residues and USDA Pesticide Data
Program monitoring samples for the
remaining commodities, available
E:\FR\FM\14FER1.SGM
14FER1
khammond on DSKJM1Z7X2PROD with RULES
8450
Federal Register / Vol. 85, No. 31 / Friday, February 14, 2020 / Rules and Regulations
empirical or default processing factors,
and average PCT assumptions for some
commodities.
iii. Cancer. Based on the data
summarized in Unit III.A., EPA has
concluded that a nonlinear RfD
approach is appropriate for assessing
cancer risk due to difenoconazole.
Cancer risk was assessed using the same
exposure estimates as discussed in Unit
III.C.1.ii., chronic exposure.
iv. Anticipated residue and PCT
information. Section 408(b)(2)(E) of
FFDCA authorizes EPA to use available
data and information on the anticipated
residue levels of pesticide residues in
food and the actual levels of pesticide
residues that have been measured in
food. If EPA relies on such information,
EPA must require pursuant to FFDCA
section 408(f)(1) that data be provided 5
years after the tolerance is established,
modified, or left in effect, demonstrating
that the levels in food are not above the
levels anticipated. For the present
action, EPA will issue such data call-ins
as are required by FFDCA section
408(b)(2)(E) and authorized under
FFDCA section 408(f)(1). Data will be
required to be submitted no later than
5 years from the date of issuance of
these tolerances.
Section 408(b)(2)(F) of FFDCA states
that the Agency may use data on the
actual percent of food treated for
assessing chronic dietary risk only if:
• Condition a: The data used are
reliable and provide a valid basis to
show what percentage of the food
derived from such crop is likely to
contain the pesticide residue.
• Condition b: The exposure estimate
does not underestimate exposure for any
significant subpopulation group.
• Condition c: Data are available on
pesticide use and food consumption in
a particular area, the exposure estimate
does not understate exposure for the
population in such area.
In addition, the Agency must provide
for periodic evaluation of any estimates
used. To provide for the periodic
evaluation of the estimate of PCT as
required by FFDCA section 408(b)(2)(F),
EPA may require registrants to submit
data on PCT.
The Agency estimated the PCT for
existing uses as follows: Almond 15%,
apples 25%, apricot 10%, artichoke
15%, blueberry 10%, broccoli 2.5%,
cabbage 10%, cantaloupe 2.5%, carrot
2.5%, cauliflower 2.5%, cherry 2.5%,
cucumbers 5%, garlic 10%, grapefruit
10%, grape (raisin) 10%, grape (table)
25%, grape (wine) 15%, hazelnut 2.5%,
lemon 5%, onions 10%, orange 5%,
peach 10%, pear 10%, pecan 5%,
peppers 15%, pistachio 10%, plum/
prune 10%, potato 20%, pumpkin 5%,
VerDate Sep<11>2014
17:46 Feb 13, 2020
Jkt 250001
soybean 2.5%, squash 10%, strawberry
2.5%, sugar beets 20%, sweet corn 5%,
tangerine 5%, tomato 35%, walnut 5%,
watermelon 15%, and wheat 15%.
In most cases, EPA uses available data
from United States Department of
Agriculture/National Agricultural
Statistics Service (USDA/NASS),
proprietary market surveys, and
California Department of Pesticide
Regulation (CalDPR) Pesticide Use
Reporting (PUR) for the chemical/crop
combination for the most recent 10
years. EPA uses an average PCT for
chronic dietary risk analysis. The
average PCT figures for each existing
use is derived by combining available
public and private market survey data
for that use, averaging across all
observations, and rounding up to the
nearest 5%, except for those situations
in which the average PCT is less than
1% or less than 2.5%. In those cases, the
Agency would use less than 1% or less
than 2.5% as the average PCT value,
respectively. The maximum PCT figure
is the highest observed maximum value
reported within the most recent 10 years
of available public and private market
survey data for the existing use and
rounded up to the nearest multiple of
5%, except where the maximum PCT is
less than 2.5%, in which case, the
Agency uses less than 2.5% as the
maximum PCT.
The Agency believes that the three
conditions discussed in Unit III.C.1.iv.
have been met. With respect to
Condition a, PCT estimates are derived
from Federal and private market survey
data, which are reliable and have a valid
basis. The Agency is reasonably certain
that the percentage of the food treated
is not likely to be an underestimation.
As to Conditions b and c, regional
consumption information and
consumption information for significant
subpopulations is taken into account
through EPA’s computer-based model
for evaluating the exposure of
significant subpopulations including
several regional groups. Use of this
consumption information in EPA’s risk
assessment process ensures that EPA’s
exposure estimate does not understate
exposure for any significant
subpopulation group and allows the
Agency to be reasonably certain that no
regional population is exposed to
residue levels higher than those
estimated by the Agency. Other than the
data available through national food
consumption surveys, EPA does not
have available reliable information on
the regional consumption of food to
which difenoconazole may be applied
in a particular area.
2. Dietary exposure from drinking
water. The drinking water assessment
PO 00000
Frm 00078
Fmt 4700
Sfmt 4700
was performed using a total toxic
residue method, which considers both
parent difenoconazole and its major
metabolite, CGA 205375, or total toxic
residues (TTR) from difenoconazole
uses, in surface and groundwater. The
Agency used screening level water
exposure models in the dietary exposure
analysis and risk assessment for
difenoconazole in drinking water. These
simulation models take into account
data on the physical, chemical, and fate/
transport characteristics of
difenoconazole plus CGA 205375.
Further information regarding EPA
drinking water models used in pesticide
exposure assessment can be found at
https://www2.epa.gov/pesticide-scienceand-assessing-pesticide-risks/aboutwater-exposure-models-used-pesticide.
Based on the Tier II Pesticide in Water
Calculator (PWC v1.52) model and Tier
1 Rice Model, the estimated drinking
water concentrations (EDWCs) of TTR of
difenoconazole for acute exposures are
estimated to be 33.4 parts per billion
(ppb) for surface water and 2.0 ppb for
ground water. Chronic exposure EDWCs
for non-cancer assessments are
estimated to be 27.4 ppb for surface
water and 0.60 ppb for ground water.
Modeled estimates of drinking water
concentrations were directly entered
into the dietary exposure model. For
acute dietary risk assessment, the water
concentration value of 33.4 ppb was
used to assess the contribution to
drinking water. For chronic dietary risk
assessment, the water concentration of
value 27.4 ppb was used to assess the
contribution to drinking water.
3. From non-dietary exposure. The
term ‘‘residential exposure’’ is used in
this document to refer to nonoccupational, non-dietary exposure
(e.g., for lawn and garden pest control,
indoor pest control, termiticides, and
flea and tick control on pets).
Difenoconazole is currently registered
for the following uses that could result
in residential exposures: Treatment of
ornamental plants in commercial and
residential landscapes and interior
plantscapes as well as turf applications
to golf courses. EPA assessed residential
exposure using the following
assumptions: For residential handlers,
adult short-term dermal and inhalation
exposure is expected from mixing,
loading, and applying difenoconazole
on ornamentals (gardens and trees). For
residential post-application exposures,
short-term dermal exposure is expected
for both adults and children (6 < 11
years old and 11 < 16 years old) from
post-application activities in treated
residential landscapes and on golf
courses. There are no residential uses
E:\FR\FM\14FER1.SGM
14FER1
khammond on DSKJM1Z7X2PROD with RULES
Federal Register / Vol. 85, No. 31 / Friday, February 14, 2020 / Rules and Regulations
for difenoconazole that would result in
incidental oral exposure to children.
The scenarios used in the aggregate
assessment were those that resulted in
the highest exposures. The highest
exposures consist of the short-term
dermal exposure to adults from postapplication activities in treated gardens
and short-term dermal exposure to
children 6 to 11 years old from postapplication activities in treated gardens.
Further information regarding EPA
standard assumptions and generic
inputs for residential exposures may be
found at https://www2.epa.gov/pesticidescience-and-assessing-pesticide-risks/
standard-operating-proceduresresidential-pesticide.
4. Cumulative effects from substances
with a common mechanism of toxicity.
Section 408(b)(2)(D)(v) of FFDCA
requires that, when considering whether
to establish, modify, or revoke a
tolerance, the Agency consider
‘‘available information’’ concerning the
cumulative effects of a particular
pesticide’s residues and ‘‘other
substances that have a common
mechanism of toxicity.’’
Unlike other pesticides for which EPA
has followed a cumulative risk approach
based on a common mechanism of
toxicity, EPA has not made a common
mechanism of toxicity finding as to
difenoconazole and any other
substances, although EPA has
previously concluded that there are no
conclusive data that difenoconazole
shares a common mechanism of toxicity
with other conazole pesticides.
Although the conazole fungicides
(triazoles) produce 1,2,4 triazole and its
acid-conjugated metabolites
(triazolylalanine and triazolylacetic
acid), 1,2,4 triazole and its acidconjugated metabolites do not
contribute to the toxicity of the parent
conazole fungicides (triazoles). A
separate aggregate risk assessment was
conducted for triazole and the
conjugated triazole metabolites
(Common Triazole Metabolites:
Updated Aggregate Human Health Risk
Assessment to Address New Section 3
Registrations For Use of Difenoconazole
and Mefentrifluconazole; DP451447,
dated May 15, 2019) and it can be found
at https://www.regulations.gov at docket
ID number EPA–HQ–OPP–2018–0002.
These new uses of difenoconazole
considered with existing uses of triazole
compounds do not result in a risk of
concern for 1,2,4-trizaole and its
metabolites. Difenoconazole does not
appear to produce any other toxic
metabolite produced by other
substances. For the purposes of this
action, therefore, EPA has not assumed
that difenoconazole has a common
VerDate Sep<11>2014
17:46 Feb 13, 2020
Jkt 250001
mechanism of toxicity with other
substances. For information regarding
EPA’s efforts to determine which
chemicals have a common mechanism
of toxicity and to evaluate the
cumulative effects of such chemicals,
see EPA’s website at https://
www.epa.gov/pesticide-science-andassessing-pesticide-risks/cumulativeassessment-risk-pesticides.
D. Safety Factor for Infants and
Children
1. In general. Section 408(b)(2)(C) of
FFDCA provides that EPA shall apply
an additional tenfold (10X) margin of
safety for infants and children in the
case of threshold effects to account for
prenatal and postnatal toxicity and the
completeness of the database on toxicity
and exposure unless EPA determines
based on reliable data that a different
margin of safety will be safe for infants
and children. This additional margin of
safety is commonly referred to as the
FQPA Safety Factor (SF). In applying
this provision, EPA either retains the
default value of 10X, or uses a different
additional safety factor when reliable
data available to EPA support the choice
of a different factor.
2. Prenatal and postnatal sensitivity.
The available toxicity studies indicated
no increased quantitative susceptibility
of rats or rabbits from in utero or
postnatal exposure to difenoconazole. In
prenatal developmental toxicity studies
in rats and rabbits and in the 2generation reproduction study in rats,
fetal/offspring toxicity, when observed,
occurred at equivalent or higher doses
than in the maternal/parental animals.
In rabbits there was qualitative
susceptibility since the developmental
effects were more severe than the
maternal effects seen at the same dose;
however, the selected POD is protective
of this effect. In a rat developmental
toxicity study, developmental effects
were observed at doses higher than
those which caused maternal toxicity.
Developmental effects in the rat
included increased incidence of
ossification of the thoracic vertebrae and
hyoid, decreased number of sternal
centers of ossification, increased
number of ribs and thoracic vertebrae,
and decreased number of lumbar
vertebrae. In the rabbit study,
developmental effects (increases in postimplantation loss and resorptions and
decreases in fetal body weight) were
also seen at maternally toxic (decreased
body weight gain and food
consumption) doses. In the twogeneration reproduction study in rats,
toxicity to the fetuses/offspring
(reduction in the body weight of F1
male pups), when observed, occurred at
PO 00000
Frm 00079
Fmt 4700
Sfmt 4700
8451
equivalent or higher doses than in the
maternal/parental animals (reductions
in body weight gain).
3. Conclusion. EPA has determined
that reliable data show the safety of
infants and children would be
adequately protected if the FQPA SF
were reduced to 1X. That decision is
based on the following findings:
i. The toxicity database for
difenoconazole is sufficient for a full
hazard evaluation and is considered
adequate to evaluate risks to infants and
children.
ii. There are no clear signs indication
that difenoconazole is a neurotoxic
chemical following acute, subchronic,
or chronic dosing in multiple species in
the difenoconazole database. The effects
observed in acute and subchronic
neurotoxicity studies are considered
non-adverse as they were transient in
nature and were only observed in one
sex (males as reduced fore-limb grip
strength with no histologic findings)
and the selected endpoints of toxicity
for risk assessment are protective of any
potential neurotoxicity. There is no
need for a developmental neurotoxicity
study or additional UFs to account for
neurotoxicity.
iii. There is no evidence that
difenoconazole results in increased
quantitative susceptibility in in utero
rats or rabbits in the prenatal
developmental studies or in young rats
in the 2-generation reproduction study.
However, in the developmental toxicity
study in rabbits, developmental effects
(increases in post-implantation loss and
resorptions and decreases in fetal body
weight) were also seen at maternally
toxic doses (decreased body weight gain
and food consumption). Because these
effects are more severe, qualitative
susceptibility is evident in the rabbit.
The PODs selected to assess dietary
exposures are protective of these effects.
iv. There are no residual uncertainties
identified in the exposure databases.
The dietary food exposure assessments
were performed based on tolerance-level
residues and 100% CT for the acute
assessment while the chronic
assessment used USDA Pesticide Data
Program (PDP) monitoring data, average
field trial residues for some
commodities, tolerance level residues
for remaining commodities, and average
percent crop treated for some
commodities. These assumptions will
not underestimate dietary exposure to
difenoconazole. EPA made conservative
(protective) assumptions in the ground
and surface water modeling used to
assess exposure to difenoconazole in
drinking water. EPA used similarly
conservative assumptions to assess postapplication exposure of children. These
E:\FR\FM\14FER1.SGM
14FER1
8452
Federal Register / Vol. 85, No. 31 / Friday, February 14, 2020 / Rules and Regulations
khammond on DSKJM1Z7X2PROD with RULES
assessments will not underestimate the
exposure and risks posed by
difenoconazole.
E. Aggregate Risks and Determination of
Safety
EPA determines whether acute and
chronic dietary pesticide exposures are
safe by comparing aggregate exposure
estimates to the aPAD and cPAD. For
linear cancer risks, EPA calculates the
lifetime probability of acquiring cancer
given the estimated aggregate exposure.
Short-, intermediate-, and chronic-term
risks are evaluated by comparing the
estimated aggregate food, water, and
residential exposure to the appropriate
PODs to ensure that an adequate MOE
exists.
1. Acute risk. Using the exposure
assumptions discussed in this unit for
acute exposure, the acute dietary
exposure from food and water to
difenoconazole will occupy 52% of the
aPAD for all infants <1 year old, the
population group receiving the greatest
exposure.
2. Chronic risk. Using the exposure
assumptions described in this unit for
chronic exposure, EPA has concluded
that chronic exposure to difenoconazole
from food and water will utilize 53% of
the cPAD for all infants <1 year old, the
population group receiving the greatest
exposure. Based on the explanation in
Unit III.C.3., regarding residential use
patterns, chronic residential exposure to
residues of difenoconazole is not
expected.
3. Short-term risk. Short-term
aggregate exposure takes into account
short-term residential exposure plus
average exposure levels to food and
water (considered to be a background
exposure level). Difenoconazole is
currently registered for uses that could
result in short-term residential
exposure, and the Agency has
determined that it is appropriate to
aggregate chronic exposure through food
and water with short-term residential
exposures to difenoconazole.
Using the exposure assumptions
described in this unit for short-term
exposures, EPA has concluded the
combined short-term food, water, and
residential exposures result in aggregate
MOEs of 180 for adults and 240 for
children 6 to <11 years old. Because
EPA’s level of concern for
difenoconazole is an MOE of 100 or
below, these MOEs are not of concern.
4. Intermediate-term risk.
Intermediate-term aggregate exposure
takes into account intermediate-term
residential exposure plus chronic
exposure to food and water (considered
to be a background exposure level). An
intermediate-term adverse effect was
VerDate Sep<11>2014
17:46 Feb 13, 2020
Jkt 250001
identified; however, difenoconazole is
not registered for any use patterns that
would result in intermediate-term
residential exposure. Intermediate-term
risk is assessed based on intermediateterm residential exposure plus chronic
dietary exposure. Because there is no
intermediate-term residential exposure
and chronic dietary exposure has
already been assessed under the
appropriately protective cPAD (which is
at least as protective as the POD used to
assess intermediate-term risk), no
further assessment of intermediate-term
risk is necessary, and EPA relies on the
chronic dietary risk assessment for
evaluating intermediate-term risk for
difenoconazole.
5. Aggregate cancer risk for U.S.
population. As discussed in Unit III.A.,
EPA has determined that use of the
chronic reference dose will be
protective of the potential for cancer
risk. Because the chronic exposure does
not exceed the Agency’s level of
concern, EPA concludes that exposure
to difenoconazole would not pose an
unacceptable cancer risk.
6. Determination of safety. Based on
these risk assessments, EPA concludes
that there is a reasonable certainty that
no harm will result to the general
population, or to infants and children
from aggregate exposure to
difenoconazole residues.
IV. Other Considerations
A. Analytical Enforcement Methodology
An adequate tolerance enforcement
method, gas chromatography with
nitrogen-phosphorus detection (GC/
NPD) method AG–575B, is available for
the determination of residues of
difenoconazole in/on plant
commodities. An adequate enforcement
method, gas chromatography with mass
spectrometry detection (GC/MSD)
method AG–676A, is also available for
the determination of residues of
difenoconazole per se in/on canola and
barley commodities. A confirmatory
method, GC/MSD method AG–676, is
also available.
An adequate tolerance enforcement
method, Method REM 147.07b, is
available for livestock commodities. The
method determines residues of
difenoconazole and CGA–205375 in
livestock commodities by liquid
chromatography with tandem mass
spectrometry detection (LC–MS/MS).
Adequate confirmatory methods,
Method AG–544A and Method REM
147.06, are available for the
determination of residues of
difenoconazole and CGA–205375,
respectively, in livestock commodities.
PO 00000
Frm 00080
Fmt 4700
Sfmt 4700
The method may be requested from:
Chief, Analytical Chemistry Branch,
Environmental Science Center, 701
Mapes Rd., Ft. Meade, MD 20755–5350;
telephone number: (410) 305–2905;
email address: residuemethods@
epa.gov.
B. International Residue Limits
In making its tolerance decisions, EPA
seeks to harmonize U.S. tolerances with
international standards whenever
possible, consistent with U.S. food
safety standards and agricultural
practices. EPA considers the
international maximum residue limits
(MRLs) established by the Codex
Alimentarius Commission (Codex), as
required by FFDCA section 408(b)(4).
The Codex Alimentarius is a joint
United Nations Food and Agriculture
Organization/World Health
Organization food standards program,
and it is recognized as an international
food safety standards-setting
organization in trade agreements to
which the United States is a party. EPA
may establish a tolerance that is
different from a Codex MRL; however,
FFDCA section 408(b)(4) requires that
EPA explain the reasons for departing
from the Codex level.
Codex has established MRLs for
difenoconazole in or on carrot at 0.2
ppm; edible offal at 1.5 ppm; sugar beet
at 0.2 ppm; ginseng at 0.08 ppm;
ginseng, dried at 0.8 ppm; and ginseng,
extracts at 0.6 ppm. Several of these
MRLs are different than the tolerances
established for difenoconazole in the
United States. The U.S. tolerance in/on
crop subgroup 1A, except ginseng (0.6
ppm), being established in this
rulemaking, is based on radish root data
and cannot be harmonized with the
Codex MRL for carrot, which is lower
than the subgroup tolerance; doing so
could result in exceedances of the
tolerances even when growers followed
label directions. The U.S. tolerance for
ginseng has been harmonized with the
Codex MRL for ginseng, dried and is
inclusive of the lower tolerances for
ginseng and ginseng, extracts. The
tolerances for cattle, liver; goat, liver;
horse, liver; and sheep, liver cannot be
harmonized with Codex MRLs due to
different dietary burdens.
C. Response to Comments
EPA received one comment opposing
pesticide residues in food, although no
substantive information was provided
for EPA to take into consideration in its
safety assessment. Although the
commenter generally expressed concern
about the potential for exposure to
difenoconazole to be carcinogenic, EPA
has evaluated the available data on
E:\FR\FM\14FER1.SGM
14FER1
khammond on DSKJM1Z7X2PROD with RULES
Federal Register / Vol. 85, No. 31 / Friday, February 14, 2020 / Rules and Regulations
carcinogenicity and exposure and
determined that aggregate exposure to
difenoconazole will not cause a cancer
risk. The FFDCA authorizes EPA to
establish tolerances that permit certain
levels of pesticide residues in or on food
when the Agency can determine that
such residues are safe. EPA has made
that determination for the tolerances
subject to this action; the commenter
provided no information relevant to that
conclusion.
expires, residues of difenoconazole on
ginseng cannot exceed the new
tolerance of 0.8 ppm.
This reduction in tolerance levels is
not discriminatory; the same food safety
standard contained in the FFDCA
applies equally to domestically
produced and imported foods. The new
tolerance levels are supported by
available residue data.
D. Revisions to Petitioned-For
Tolerances
The terms ‘‘tea;’’ ‘‘root vegetable crop
subgroup 1A;’’ ‘‘leaves of root and tuber
vegetables crop group 2’’ requested in
the petition are being replaced with
‘‘tea, dried;’’ ‘‘vegetable, root, subgroup
1A, except ginseng;’’ and ‘‘vegetable,
leaves of root and tuber, group 2’’,
respectively, to reflect the correct
commodity definitions. The EPA has
modified the tolerance on tea, dried
from the requested 30 ppm to 15 ppm
to harmonize with Japan’s draft MRL.
The ginseng tolerance has been removed
from the vegetable, root, subgroup 1A
and set at 0.8 to harmonize with the
highest Codex MRL. Tolerances for
cattle, liver; goat, liver; horse, liver; and
sheep, liver have been increased from
0.40 to 0.7 ppm based on the recalculated dairy cattle dietary burden
and the available feeding study data for
residues of difenoconazole and its
metabolite CGA–205375. Trailing zeroes
have been removed from tolerances in
accordance with current Agency
practices.
Therefore, tolerances are established
for residues of difenoconazole,
difenoconazole, in or on vegetable, root,
subgroup 1A, except ginseng at 0.6ppm;
vegetable, leaves of root and tuber,
group 2 at 8 ppm; and tea, dried at 15
ppm. Tolerances are amended for
ginseng from 1.0 to 0.8 ppm; and cattle,
liver; goat, liver; horse, liver; and sheep,
liver from 0.40 ppm to 0.7 ppm. In
addition, the Agency is removing the
existing tolerances for beet, sugar; and
carrot as they are unnecessary upon the
establishment of the tolerance for
vegetable, root, subgroup 1A, except
ginseng. Finally, the Agency is
amending the existing tolerance for
ginseng by adding an expiration date.
E. International Trade Considerations
In this final rule, EPA is reducing the
existing tolerance for ginseng from 1.0
ppm to 0.8 ppm in order to harmonize
with the Codex MRL. Available residue
data demonstrates that the new
tolerance is sufficient to cover residues
on ginseng.
In accordance with the World Trade
Organization’s (WTO) Sanitary and
Phytosanitary Measures (SPS)
Agreement, EPA intends to notify the
WTO of this revision in order to satisfy
its obligation. In addition, the SPS
Agreement requires that Members
provide a ‘‘reasonable interval’’ between
the publication of a regulation subject to
the Agreement and its entry into force
to allow time for producers in exporting
Member countries to adapt to the new
requirement. At this time, EPA is
establishing an expiration date for the
existing ginseng tolerance to allow that
tolerance to remain in effect for a period
of six months after the effective date of
this final rule, in order to address this
requirement. After the six month period
VerDate Sep<11>2014
17:46 Feb 13, 2020
Jkt 250001
V. Conclusion
VI. Statutory and Executive Order
Reviews
This action establishes tolerances
under FFDCA section 408(d) in
response to a petition submitted to the
Agency. The Office of Management and
Budget (OMB) has exempted these types
of actions from review under Executive
Order 12866, entitled ‘‘Regulatory
Planning and Review’’ (58 FR 51735,
October 4, 1993). Because this action
has been exempted from review under
Executive Order 12866, this action is
not subject to Executive Order 13211,
entitled ‘‘Actions Concerning
Regulations That Significantly Affect
Energy Supply, Distribution, or Use’’ (66
FR 28355, May 22, 2001) or Executive
Order 13045, entitled ‘‘Protection of
Children from Environmental Health
Risks and Safety Risks’’ (62 FR 19885,
April 23, 1997), nor is it considered a
regulatory action under Executive Order
13771, entitled ‘‘Reducing Regulations
and Controlling Regulatory Costs’’ (82
FR 9339, February 3, 2017). This action
does not contain any information
collections subject to OMB approval
under the Paperwork Reduction Act
(PRA) (44 U.S.C. 3501 et seq.), nor does
it require any special considerations
under Executive Order 12898, entitled
‘‘Federal Actions to Address
Environmental Justice in Minority
Populations and Low-Income
Populations’’ (59 FR 7629, February 16,
1994).
PO 00000
Frm 00081
Fmt 4700
Sfmt 4700
8453
Since tolerances and exemptions that
are established on the basis of a petition
under FFDCA section 408(d), such as
the tolerance in this final rule, do not
require the issuance of a proposed rule,
the requirements of the Regulatory
Flexibility Act (RFA) (5 U.S.C. 601 et
seq.), do not apply.
This action directly regulates growers,
food processors, food handlers, and food
retailers, not States or tribes, nor does
this action alter the relationships or
distribution of power and
responsibilities established by Congress
in the preemption provisions of FFDCA
section 408(n)(4). As such, the Agency
has determined that this action will not
have a substantial direct effect on States
or tribal governments, on the
relationship between the National
Government and the States or tribal
governments, or on the distribution of
power and responsibilities among the
various levels of government or between
the Federal Government and Indian
tribes. Thus, the Agency has determined
that Executive Order 13132, entitled
‘‘Federalism’’ (64 FR 43255, August 10,
1999) and Executive Order 13175,
entitled ‘‘Consultation and Coordination
with Indian Tribal Governments’’ (65 FR
67249, November 9, 2000) do not apply
to this action. In addition, this action
does not impose any enforceable duty or
contain any unfunded mandate as
described under Title II of the Unfunded
Mandates Reform Act (UMRA) (2 U.S.C.
1501 et seq.).
This action does not involve any
technical standards that would require
Agency consideration of voluntary
consensus standards pursuant to section
12(d) of the National Technology
Transfer and Advancement Act
(NTTAA) (15 U.S.C. 272 note).
VII. Congressional Review Act
Pursuant to the Congressional Review
Act (5 U.S.C. 801 et seq.), EPA will
submit a report containing this rule and
other required information to the U.S.
Senate, the U.S. House of
Representatives, and the Comptroller
General of the United States prior to
publication of the rule in the Federal
Register. This action is not a ‘‘major
rule’’ as defined by 5 U.S.C. 804(2).
List of Subjects in 40 CFR Part 180
Environmental protection,
Administrative practice and procedure,
Agricultural commodities, Pesticides
and pests, Reporting and recordkeeping
requirements.
E:\FR\FM\14FER1.SGM
14FER1
8454
Federal Register / Vol. 85, No. 31 / Friday, February 14, 2020 / Rules and Regulations
Dated: December 19, 2019.
Michael Goodis,
Director, Registration Division, Office of
Pesticide Programs.
Parts per
million
Commodity
*
*
*
*
Sheep, liver .................................
Therefore, 40 CFR chapter I is
amended as follows:
*
PART 180—[AMENDED]
*
1. The authority citation for part 180
continues to read as follows:
■
*
*
*
*
*
0.7
*
*
[FR Doc. 2020–02241 Filed 2–13–20; 8:45 am]
BILLING CODE 6560–50–P
Authority: 21 U.S.C. 321(q), 346a and 371.
2. In § 180.475:
a. In the table in paragraph (a)(1):
i. Remove the entries ‘‘Beet, sugar’’
and ‘‘Carrot’’.
■ ii. Revise the entry for ‘‘Ginseng’’.
■ iii. Add a second entry for ‘‘Ginseng’’
after the existing entry for ‘‘Ginseng’’
and add alphabetically the entries ‘‘Tea,
dried’’; ‘‘Vegetable, leaves of root and
tuber, group 2’’; and ‘‘Vegetable, root,
subgroup 1A, except ginseng’’.
■ iv. Add footnotes 1 and 2 to the end
of the table.
■ b. Revise the entries ‘‘Cattle, liver’’;
‘‘Goat, liver’’; ‘‘Horse, liver’’; and
‘‘Sheep, liver’’ in the table in paragraph
(a)(2).
The additions and revisions read as
follows:
■
■
■
§ 180.475 Difenoconazole; tolerances for
residues.
(a) * * *
(1) * * *
Parts per
million
Commodity
*
*
*
*
Ginseng 2 ....................................
Ginseng ......................................
*
*
*
*
*
Tea, dried 1 .................................
*
*
*
*
*
Vegetable, leaves of root and
tuber, group 2 .........................
Vegetable, root, subgroup 1A,
except ginseng ........................
*
*
*
*
1.0
0.8
15
8
0.6
*
*
1 There
are no U.S. registrations for these
commodities.
2 This tolerance expires on August 14, 2020.
(2) * * *
Parts per
million
khammond on DSKJM1Z7X2PROD with RULES
Commodity
*
*
*
*
Cattle, liver ..................................
*
*
*
*
*
Goat, liver ...................................
*
*
*
*
*
Horse, liver .................................
*
VerDate Sep<11>2014
17:46 Feb 13, 2020
Jkt 250001
0.7
0.7
0.7
ENVIRONMENTAL PROTECTION
AGENCY
40 CFR Part 180
[EPA–HQ–OPP–2017–0694; FRL–10004–23]
Cyantraniliprole; Pesticide Tolerances
Environmental Protection
Agency (EPA).
ACTION: Final rule.
AGENCY:
This regulation establishes a
tolerance for residues of
cyantraniliprole in or on strawberry.
The Interregional Research Project No. 4
(IR–4) requested this tolerance under
the Federal Food, Drug, and Cosmetic
Act (FFDCA).
DATES: This regulation is effective
February 14, 2020. Objections and
requests for hearings must be received
on or before April 14, 2020 and must be
filed in accordance with the instructions
provided in 40 CFR part 178 (see also
Unit I.C. of the SUPPLEMENTARY
INFORMATION).
ADDRESSES: The docket for this action,
identified by docket identification (ID)
number EPA–HQ–OPP–2017–0694, is
available at https://www.regulations.gov
or at the Office of Pesticide Programs
Regulatory Public Docket (OPP Docket)
in the Environmental Protection Agency
Docket Center (EPA/DC), West William
Jefferson Clinton Bldg., Rm. 3334, 1301
Constitution Ave. NW, Washington, DC
20460–0001. The Public Reading Room
is open from 8:30 a.m. to 4:30 p.m.,
Monday through Friday, excluding legal
holidays. The telephone number for the
Public Reading Room is (202) 566–1744,
and the telephone number for the OPP
Docket is (703) 305–5805. Please review
the visitor instructions and additional
information about the docket available
at https://www.epa.gov/dockets.
FOR FURTHER INFORMATION CONTACT:
Michael Goodis, Registration Division
(7505P), Office of Pesticide Programs,
Environmental Protection Agency, 1200
Pennsylvania Ave. NW, Washington, DC
20460–0001; main telephone number:
(703) 305–7090; email address:
RDFRNotices@epa.gov.
SUMMARY:
PO 00000
Frm 00082
Fmt 4700
Sfmt 4700
I. General Information
A. Does this action apply to me?
*
*
SUPPLEMENTARY INFORMATION:
You may be potentially affected by
this action if you are an agricultural
producer, food manufacturer, or
pesticide manufacturer. The following
list of North American Industrial
Classification System (NAICS) codes is
not intended to be exhaustive, but rather
provides a guide to help readers
determine whether this document
applies to them. Potentially affected
entities may include:
• Crop production (NAICS code 111).
• Animal production (NAICS code
112).
• Food manufacturing (NAICS code
311).
• Pesticide manufacturing (NAICS
code 32532).
B. How can I get electronic access to
other related information?
You may access a frequently updated
electronic version of EPA’s tolerance
regulations at 40 CFR part 180 through
the Government Publishing Office’s eCFR site at https://www.ecfr.gov/cgi-bin/
text-idx?&c=ecfr&tpl=/ecfrbrowse/
Title40/40tab_02.tpl. To access the
OCSPP test guidelines referenced in this
document electronically, please go to
https://www.epa.gov/aboutepa/aboutoffice-chemical-safety-and-pollutionprevention-ocspp and select ‘‘Test
Methods and Guidelines.’’
C. How can I file an objection or hearing
request?
Under FFDCA section 408(g), 21
U.S.C. 346a, any person may file an
objection to any aspect of this regulation
and may also request a hearing on those
objections. You must file your objection
or request a hearing on this regulation
in accordance with the instructions
provided in 40 CFR part 178. To ensure
proper receipt by EPA, you must
identify docket ID number EPA–HQ–
OPP–2017–0694 in the subject line on
the first page of your submission. All
objections and requests for a hearing
must be in writing and must be received
by the Hearing Clerk on or before April
14, 2020. Addresses for mail and hand
delivery of objections and hearing
requests are provided in 40 CFR
178.25(b).
In addition to filing an objection or
hearing request with the Hearing Clerk
as described in 40 CFR part 178, please
submit a copy of the filing (excluding
any Confidential Business Information
(CBI)) for inclusion in the public docket.
Information not marked confidential
pursuant to 40 CFR part 2 may be
E:\FR\FM\14FER1.SGM
14FER1
Agencies
[Federal Register Volume 85, Number 31 (Friday, February 14, 2020)]
[Rules and Regulations]
[Pages 8447-8454]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-02241]
-----------------------------------------------------------------------
ENVIRONMENTAL PROTECTION AGENCY
40 CFR Part 180
[EPA-HQ-OPP-2018-0718 and EPA-HQ-OPP-2019-0076; FRL-10002-06]
Difenoconazole; Pesticide Tolerances
AGENCY: Environmental Protection Agency (EPA).
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: This regulation establishes tolerances for residues of
difenoconazole in or on vegetable, root, subgroup 1A, except ginseng;
vegetable, leaves of root and tuber, group 2; and tea, dried. In
addition, this regulation amends the tolerances for residues of
difenoconazole in or ginseng; cattle, liver; goat, liver; horse, liver;
and sheep, liver. Syngenta Crop Protection, LLC requested these
tolerances under the Federal Food, Drug, and Cosmetic Act (FFDCA).
DATES: This regulation is effective February 14, 2020. Objections and
requests for hearings must be received on or before April 14, 2020, and
must be filed in accordance with the instructions provided in 40 CFR
part 178 (see also Unit I.C. of the SUPPLEMENTARY INFORMATION).
ADDRESSES: The docket for this action, identified by docket
identification (ID) number EPA-HQ-OPP-2018-0718 and EPA-HQ-OPP-2019-
0076, is available at https://www.regulations.gov or at the Office of
Pesticide Programs Regulatory Public Docket (OPP Docket) in the
Environmental Protection Agency Docket Center (EPA/DC), West William
Jefferson Clinton Bldg., Rm. 3334, 1301 Constitution Ave. NW,
Washington, DC 20460-0001. The Public Reading Room is open from 8:30
a.m. to 4:30 p.m., Monday through Friday, excluding legal holidays. The
telephone number for the Public Reading Room is (202) 566-1744, and the
telephone number for the OPP Docket is (703) 305-5805. Please review
the visitor instructions and additional information about the docket
available at https://www.epa.gov/dockets.
FOR FURTHER INFORMATION CONTACT: Michael Goodis, Registration Division
(7505P), Office of Pesticide Programs, Environmental Protection Agency,
1200 Pennsylvania Ave. NW, Washington, DC 20460-0001; main telephone
number: (703) 305-7090; email address: [email protected].
SUPPLEMENTARY INFORMATION:
I. General Information
A. Does this action apply to me?
You may be potentially affected by this action if you are an
agricultural producer, food manufacturer, or pesticide manufacturer.
The following list of North American Industrial Classification System
(NAICS) codes is not intended to be exhaustive, but rather provides a
guide to help readers determine whether this document applies to them.
Potentially affected entities may include:
Crop production (NAICS code 111)
Animal production (NAICS code 112)
Food manufacturing (NAICS code 311)
Pesticide manufacturing (NAICS code 32532)
B. How can I get electronic access to other related information?
You may access a frequently updated electronic version of EPA's
tolerance regulations at 40 CFR part 180 through the Government
Publishing Office's e-CFR site at https://www.ecfr.gov/cgi-bin/text-idx?&c=ecfr&tpl=/ecfrbrowse/Title40/40tab_02.tpl.
C. How can I file an objection or hearing request?
Under FFDCA section 408(g), 21 U.S.C. 346a, any person may file an
objection to any aspect of this regulation and may also request a
hearing on those objections. You must file your objection or request a
hearing on this regulation in accordance with the instructions provided
in 40 CFR part 178. To ensure proper receipt by EPA, you must identify
docket ID number EPA-HQ-OPP-2018-0718 and EPA-HQ-OPP-2019-0076 in the
subject line on the first page of your submission. All objections and
requests for a hearing must be in writing, and must be received by the
Hearing Clerk on or before April 14, 2020. Addresses for mail and hand
delivery of objections and hearing requests are provided in 40 CFR
178.25(b).
In addition to filing an objection or hearing request with the
Hearing Clerk as described in 40 CFR part 178, please submit a copy of
the filing (excluding any Confidential Business Information (CBI)) for
inclusion in the public docket. Information not marked confidential
pursuant to 40 CFR part 2 may be disclosed publicly by EPA without
prior notice. Submit the non-CBI copy of your objection or hearing
request, identified by docket ID number EPA-HQ-OPP-2018-0718 and EPA-
HQ-OPP-2019-0076, by one of the following methods:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the online instructions for submitting comments. Do not submit
electronically any information you consider to be CBI or other
information whose disclosure is restricted by statute.
Mail: OPP Docket, Environmental Protection Agency Docket
Center (EPA/DC), (28221T), 1200 Pennsylvania Ave. NW, Washington, DC
20460-0001.
Hand Delivery: To make special arrangements for hand
delivery or delivery of boxed information, please follow the
instructions at https://www.epa.gov/dockets/contacts.html.
Additional instructions on commenting or visiting the docket, along
with more information about dockets generally, is available at https://www.epa.gov/dockets.
II. Summary of Petitioned-For Tolerance
In the Federal Register of June 7, 2019 (84 FR 26630) (FRL-9993-93)
and in the Federal Register of May 9, 2019 (84 FR 20320) (FRL-9992-36),
EPA issued documents pursuant to FFDCA section 408(d)(3), 21 U.S.C.
346a(d)(3), announcing the filing of pesticide petitions (PP 8F8695 and
8E8728, respectively) by Syngenta Crop Protection, LLC, P.O. Box 18300,
Greensboro, NC 27419. Pesticide
[[Page 8448]]
petition 8F8695 requested that 40 CFR 180.475 be amended by
establishing tolerances for residues of the fungicide difenoconazole in
or on root vegetable crop subgroup 1A at 0.60 parts per million (ppm)
and leaves of root and tuber vegetables crop group 2 at 8.0 ppm; PP
8E8728 requested the establishment of a tolerance for residues of
difenoconazole in or on tea at 30 ppm. Those documents referenced
summaries of the petitions prepared by Syngenta Crop Protection, LLC,
the registrant, which are available in their respective dockets, https://www.regulations.gov. One comment was received on EPA's May 9, 2019
notice of filing in docket number EPA-HQ-OPP-2019-0076. EPA's response
to this comment is discussed in Unit IV.C.
Based upon review of the data supporting the petition, EPA is
establishing tolerances that vary from what the petitioner requested as
permitted by FFDCA section 408(d)(4)(A)(i). These differences are
explained in Unit IV.D.
III. Aggregate Risk Assessment and Determination of Safety
Section 408(b)(2)(A)(i) of FFDCA allows EPA to establish a
tolerance (the legal limit for a pesticide chemical residue in or on a
food) only if EPA determines that the tolerance is ``safe.'' Section
408(b)(2)(A)(ii) of FFDCA defines ``safe'' to mean that ``there is a
reasonable certainty that no harm will result from aggregate exposure
to the pesticide chemical residue, including all anticipated dietary
exposures and all other exposures for which there is reliable
information.'' This includes exposure through drinking water and in
residential settings, but does not include occupational exposure.
Section 408(b)(2)(C) of FFDCA requires EPA to give special
consideration to exposure of infants and children to the pesticide
chemical residue in establishing a tolerance and to ``ensure that there
is a reasonable certainty that no harm will result to infants and
children from aggregate exposure to the pesticide chemical residue. . .
.''
Consistent with FFDCA section 408(b)(2)(D), and the factors
specified in FFDCA section 408(b)(2)(D), EPA has reviewed the available
scientific data and other relevant information in support of this
action. EPA has sufficient data to assess the hazards of and to make a
determination on aggregate exposure for difenoconazole including
exposure resulting from the tolerances established by this action.
EPA's assessment of exposures and risks associated with difenoconazole
follows.
A. Toxicological Profile
EPA has evaluated the available toxicity data and considered its
validity, completeness, and reliability as well as the relationship of
the results of the studies to human risk. EPA has also considered
available information concerning the variability of the sensitivities
of major identifiable subgroups of consumers, including infants and
children.
Subchronic and chronic toxicity studies with difenoconazole in mice
and rats showed decreased body weights and effects on the liver (e.g.,
hepatocellular hypertrophy, liver necrosis, fatty changes in the
liver). No systemic toxicity was observed at the limit dose in a rat
dermal toxicity study. Difenoconazole exhibits low acute toxicity by
the oral, dermal and inhalation routes of exposure. It is not an eye or
skin irritant and is not a sensitizer.
Acute and subchronic neurotoxicity studies showed evidence of mild
neurotoxic effects. However, the selected endpoints of toxicity for
risk assessment are protective of any potential neurotoxicity.
The available toxicity studies indicated no increased
susceptibility of rats or rabbits from in utero or postnatal exposure
to difenoconazole. In prenatal developmental toxicity studies in rats
and rabbits and in the 2-generation reproduction study in rats, fetal
and offspring toxicity, when observed, occurred at equivalent or higher
doses than in the maternal and parental animals. In a rat developmental
toxicity study, developmental effects were observed at doses higher
than those which caused maternal toxicity. Developmental effects in the
rat included increased incidence of ossification of the thoracic
vertebrae and thyroid, decreased number of sternal centers of
ossification, increased number of ribs and thoracic vertebrae, and
decreased number of lumbar vertebrae. In the rabbit study,
developmental effects (increases in post-implantation loss and
resorptions and decreases in fetal body weight) were also seen at
maternally toxic (decreased body weight gain and food consumption)
doses. Since the developmental effects are more severe than the
maternal effects, qualitative susceptibility is indicated in the rabbit
developmental study; however, the selected POD is protective of this
effect. In the 2-generation reproduction study in rats, toxicity to the
fetuses and offspring, when observed, occurred at equivalent or higher
doses than in the maternal and parental animals.
Although there is some evidence that difenoconazole affects
antibody levels at doses that cause systemic toxicity, there are no
indications in the available studies that organs associated with immune
function, such as the thymus and spleen, are affected by
difenoconazole. Difenoconazole is not mutagenic or genotoxic, and no
evidence of carcinogenicity was seen in rats. Evidence for
carcinogenicity was seen in mice as induction of liver tumors at doses
which were considered to be excessively high for carcinogenicity
testing. Difenoconazole has been classified as ``Suggestive Evidence of
Carcinogenic Potential'' based on liver tumors observed in mice. EPA
has concluded that the chronic point of departure (POD) for assessing
chronic risk will be protective of any cancer effects for the following
reasons: (1) Tumors were seen in only one species; (2) carcinoma tumors
were observed only at the two highest doses in the mouse
carcinogenicity study; (3) benign tumors and necrosis were observed at
the mid-dose; (4) the absence of tumors at the study's lower doses; (5)
the absence of genotoxic or mutagenic effects. The cRfD is well below
the no-observed- adverse-effect-level (NOAEL) of the mouse
carcinogenicity study, at which no effects on the biological endpoints
relevant to tumor development (i.e., hepatocellular hypertrophy, liver
necrosis, fatty changes in the liver and bile stasis) were seen. As a
result, EPA has concluded that a nonlinear RfD approach is appropriate
for assessing cancer risk to difenoconazole and a separate quantitative
cancer exposure assessment is unnecessary.
Specific information on the studies received and the nature of the
adverse effects caused by difenoconazole as well as the no-observed-
adverse-effect-level (NOAEL) and the lowest-observed-adverse-effect-
level (LOAEL) from the toxicity studies can be found at https://www.regulations.gov in document ``Difenoconazole. Human Health Risk
Assessment for Proposed New Foliar Uses on All Members of Vegetable,
Root, Subgroup 1A and Vegetable, Leaves of Root and Tuber, Group 2 and
Establishment of a Tolerance with No U.S. Registration in/on Imported
Tea'' in docket ID number EPA-HQ-OPP-2018-0718.
B. Toxicological Points of Departure/Levels of Concern
Once a pesticide's toxicological profile is determined, EPA
identifies toxicological POD and levels of concern to use in evaluating
the risk posed by human exposure to the pesticide. For
[[Page 8449]]
hazards that have a threshold below which there is no appreciable risk,
the toxicological POD is used as the basis for derivation of reference
values for risk assessment. PODs are developed based on a careful
analysis of the doses in each toxicological study to determine the
NOAEL and the LOAEL. Uncertainty/safety factors are used in conjunction
with the POD to calculate a safe exposure level--generally referred to
as a population-adjusted dose (PAD) or a RfD--and a safe margin of
exposure (MOE). For non-threshold risks, the Agency assumes that any
amount of exposure will lead to some degree of risk. Thus, the Agency
estimates risk in terms of the probability of an occurrence of the
adverse effect expected in a lifetime. For more information on the
general principles EPA uses in risk characterization and a complete
description of the risk assessment process, see https://www2.epa.gov/pesticide-science-and-assessing-pesticide-risks/assessing-human-health-risk-pesticides.
A summary of the toxicological endpoints for difenoconazole used
for human risk assessment is shown in Table 1 of this unit.
Table 1--Summary of Toxicological Doses and Endpoints for Difenoconazole for Use in Human Health Risk Assessment
----------------------------------------------------------------------------------------------------------------
Point of departure
Exposure scenario and uncertainty/ RfD, PAD, LOC for Study and toxicological effects
safety factors risk assessment
----------------------------------------------------------------------------------------------------------------
Acute dietary (All populations).. NOAEL = 25 mg/kg/day Acute RfD = 0.25 mg/ Acute Neurotoxicity Study in Rats.
UFA = 10x........... kg/day. LOAEL = 200 mg/kg/day in males
UFH = 10x........... aPAD = 0.25 mg/kg/ based on reduced fore-limb grip
FQPA SF = 1x........ day. strength in males on Day 1 and
increased motor activity on Day
1.
----------------------------------------------------------------------------------------------------------------
Chronic dietary (All populations) NOAEL= 0.96 mg/kg/ Chronic RfD = 0.01 Combined Chronic Toxicity/
day mg/kg/day. Carcinogenicity (rat, dietary).
UFA = 10x........... cPAD = 0.01 mg/kg/ LOAEL = 24.1/32.8 mg/kg/day (male/
UFH = 10x........... day. female) based on cumulative
FQPA SF = 1x........ decreases in body-weight gains.
----------------------------------------------------------------------------------------------------------------
Oral short-term (1 to 30 days)... NOAEL= 1.25 mg/kg/ Residential LOC for Reproduction and Fertility Study
day MOE = <100. (rat dietary).
UFA = 10x........... Parental/Offspring LOAEL = 12.5 mg/
UFH = 10x........... kg/day based on decreased pup
FQPA SF = 1x........ weight in in males on Day 21 and
reduction in body weight gain of
F0 females prior to mating,
gestation and lactation.
----------------------------------------------------------------------------------------------------------------
Dermal short-term (1 to 30 days) NOAEL = 1.25 mg/kg/ LOC for MOE = <100. Reproduction and Fertility Study
and intermediate-term (1 to 6 day (dermal (rat, dietary).
months). absorption factor = Parental/Offspring LOAEL = 12.5 mg/
6%) kg/day based on decreased pup
UFA = 10x........... weight in males on Day 21 and
UFH = 10x........... reduction in body weight gain of
FQPA SF = 1x........ F0 females prior to mating,
gestation and lactation.
----------------------------------------------------------------------------------------------------------------
Inhalation short-term (1 to 30 NOAEL= 1.25 mg/kg/ LOC for MOE = <100. Reproduction and Fertility Study
days) and intermediate-term (1 day (rat, dietary).
to 6 months). UFA = 10x........... Parental/Offspring LOAEL = 12.5 mg/
* Inhalation and oral absorption UFH = 10x........... kg/day based on decreased pup
assumed equivalent. FQPA SF = 1x........ weight in males on Day 21 and
reduction in body weight gain of
F0 females prior to mating,
gestation and lactation.
----------------------------------------------------------------------------------------------------------------
Cancer (Oral, dermal, inhalation) Difenoconazole is classified ``Suggestive Evidence of Carcinogenic
Potential''. Quantification of cancer risk is not required. The RfD would
address the concern for chronic toxicity, including carcinogenicity, likely
to result from exposure to difenoconazole.
----------------------------------------------------------------------------------------------------------------
FQPA SF = Food Quality Protection Act Safety Factor. LOAEL = lowest-observed-adverse-effect-level. LOC = level
of concern. mg/kg/day = milligram/kilogram/day. MOE = margin of exposure. NOAEL = no-observed-adverse-effect-
level. PAD = population adjusted dose (a = acute, c = chronic). RfD = reference dose. UF = uncertainty factor.
UFA = extrapolation from animal to human (interspecies). UFH = potential variation in sensitivity among
members of the human population (intraspecies).
C. Exposure Assessment
1. Dietary exposure from food and feed uses. In evaluating dietary
exposure to difenoconazole, EPA considered exposure under the
petitioned-for tolerances as well as all existing difenoconazole
tolerances in 40 CFR 180.475. EPA assessed dietary exposures from
difenoconazole in food as follows:
i. Acute exposure. Quantitative acute dietary exposure and risk
assessments are performed for a food-use pesticide, if a toxicological
study has indicated the possibility of an effect of concern occurring
as a result of a 1-day or single exposure. Such effects were identified
for difenoconazole. In estimating acute dietary exposure, EPA used food
consumption information from the United States Department of
Agriculture (USDA) National Health and Nutrition Examination Survey,
What We Eat in America, (NHANES/WWEIA) 2003 to 2008. As to residue
levels in food, EPA assumed tolerance-level residues, 100 percent crop
treated (PCT), and available empirical or default processing factors.
ii. Chronic exposure. In conducting the chronic dietary exposure
assessment EPA used the food consumption data from the USDA NHANES/
WWEIA 2003 to 2008. As to residue levels in food, EPA used tolerance-
level residues for some commodities, average field trial residues and
USDA Pesticide Data Program monitoring samples for the remaining
commodities, available
[[Page 8450]]
empirical or default processing factors, and average PCT assumptions
for some commodities.
iii. Cancer. Based on the data summarized in Unit III.A., EPA has
concluded that a nonlinear RfD approach is appropriate for assessing
cancer risk due to difenoconazole. Cancer risk was assessed using the
same exposure estimates as discussed in Unit III.C.1.ii., chronic
exposure.
iv. Anticipated residue and PCT information. Section 408(b)(2)(E)
of FFDCA authorizes EPA to use available data and information on the
anticipated residue levels of pesticide residues in food and the actual
levels of pesticide residues that have been measured in food. If EPA
relies on such information, EPA must require pursuant to FFDCA section
408(f)(1) that data be provided 5 years after the tolerance is
established, modified, or left in effect, demonstrating that the levels
in food are not above the levels anticipated. For the present action,
EPA will issue such data call-ins as are required by FFDCA section
408(b)(2)(E) and authorized under FFDCA section 408(f)(1). Data will be
required to be submitted no later than 5 years from the date of
issuance of these tolerances.
Section 408(b)(2)(F) of FFDCA states that the Agency may use data
on the actual percent of food treated for assessing chronic dietary
risk only if:
Condition a: The data used are reliable and provide a
valid basis to show what percentage of the food derived from such crop
is likely to contain the pesticide residue.
Condition b: The exposure estimate does not underestimate
exposure for any significant subpopulation group.
Condition c: Data are available on pesticide use and food
consumption in a particular area, the exposure estimate does not
understate exposure for the population in such area.
In addition, the Agency must provide for periodic evaluation of any
estimates used. To provide for the periodic evaluation of the estimate
of PCT as required by FFDCA section 408(b)(2)(F), EPA may require
registrants to submit data on PCT.
The Agency estimated the PCT for existing uses as follows: Almond
15%, apples 25%, apricot 10%, artichoke 15%, blueberry 10%, broccoli
2.5%, cabbage 10%, cantaloupe 2.5%, carrot 2.5%, cauliflower 2.5%,
cherry 2.5%, cucumbers 5%, garlic 10%, grapefruit 10%, grape (raisin)
10%, grape (table) 25%, grape (wine) 15%, hazelnut 2.5%, lemon 5%,
onions 10%, orange 5%, peach 10%, pear 10%, pecan 5%, peppers 15%,
pistachio 10%, plum/prune 10%, potato 20%, pumpkin 5%, soybean 2.5%,
squash 10%, strawberry 2.5%, sugar beets 20%, sweet corn 5%, tangerine
5%, tomato 35%, walnut 5%, watermelon 15%, and wheat 15%.
In most cases, EPA uses available data from United States
Department of Agriculture/National Agricultural Statistics Service
(USDA/NASS), proprietary market surveys, and California Department of
Pesticide Regulation (CalDPR) Pesticide Use Reporting (PUR) for the
chemical/crop combination for the most recent 10 years. EPA uses an
average PCT for chronic dietary risk analysis. The average PCT figures
for each existing use is derived by combining available public and
private market survey data for that use, averaging across all
observations, and rounding up to the nearest 5%, except for those
situations in which the average PCT is less than 1% or less than 2.5%.
In those cases, the Agency would use less than 1% or less than 2.5% as
the average PCT value, respectively. The maximum PCT figure is the
highest observed maximum value reported within the most recent 10 years
of available public and private market survey data for the existing use
and rounded up to the nearest multiple of 5%, except where the maximum
PCT is less than 2.5%, in which case, the Agency uses less than 2.5% as
the maximum PCT.
The Agency believes that the three conditions discussed in Unit
III.C.1.iv. have been met. With respect to Condition a, PCT estimates
are derived from Federal and private market survey data, which are
reliable and have a valid basis. The Agency is reasonably certain that
the percentage of the food treated is not likely to be an
underestimation. As to Conditions b and c, regional consumption
information and consumption information for significant subpopulations
is taken into account through EPA's computer-based model for evaluating
the exposure of significant subpopulations including several regional
groups. Use of this consumption information in EPA's risk assessment
process ensures that EPA's exposure estimate does not understate
exposure for any significant subpopulation group and allows the Agency
to be reasonably certain that no regional population is exposed to
residue levels higher than those estimated by the Agency. Other than
the data available through national food consumption surveys, EPA does
not have available reliable information on the regional consumption of
food to which difenoconazole may be applied in a particular area.
2. Dietary exposure from drinking water. The drinking water
assessment was performed using a total toxic residue method, which
considers both parent difenoconazole and its major metabolite, CGA
205375, or total toxic residues (TTR) from difenoconazole uses, in
surface and groundwater. The Agency used screening level water exposure
models in the dietary exposure analysis and risk assessment for
difenoconazole in drinking water. These simulation models take into
account data on the physical, chemical, and fate/transport
characteristics of difenoconazole plus CGA 205375. Further information
regarding EPA drinking water models used in pesticide exposure
assessment can be found at https://www2.epa.gov/pesticide-science-and-assessing-pesticide-risks/about-water-exposure-models-used-pesticide.
Based on the Tier II Pesticide in Water Calculator (PWC v1.52)
model and Tier 1 Rice Model, the estimated drinking water
concentrations (EDWCs) of TTR of difenoconazole for acute exposures are
estimated to be 33.4 parts per billion (ppb) for surface water and 2.0
ppb for ground water. Chronic exposure EDWCs for non-cancer assessments
are estimated to be 27.4 ppb for surface water and 0.60 ppb for ground
water.
Modeled estimates of drinking water concentrations were directly
entered into the dietary exposure model. For acute dietary risk
assessment, the water concentration value of 33.4 ppb was used to
assess the contribution to drinking water. For chronic dietary risk
assessment, the water concentration of value 27.4 ppb was used to
assess the contribution to drinking water.
3. From non-dietary exposure. The term ``residential exposure'' is
used in this document to refer to non-occupational, non-dietary
exposure (e.g., for lawn and garden pest control, indoor pest control,
termiticides, and flea and tick control on pets). Difenoconazole is
currently registered for the following uses that could result in
residential exposures: Treatment of ornamental plants in commercial and
residential landscapes and interior plantscapes as well as turf
applications to golf courses. EPA assessed residential exposure using
the following assumptions: For residential handlers, adult short-term
dermal and inhalation exposure is expected from mixing, loading, and
applying difenoconazole on ornamentals (gardens and trees). For
residential post-application exposures, short-term dermal exposure is
expected for both adults and children (6 < 11 years old and 11 < 16
years old) from post-application activities in treated residential
landscapes and on golf courses. There are no residential uses
[[Page 8451]]
for difenoconazole that would result in incidental oral exposure to
children.
The scenarios used in the aggregate assessment were those that
resulted in the highest exposures. The highest exposures consist of the
short-term dermal exposure to adults from post-application activities
in treated gardens and short-term dermal exposure to children 6 to 11
years old from post-application activities in treated gardens. Further
information regarding EPA standard assumptions and generic inputs for
residential exposures may be found at https://www2.epa.gov/pesticide-science-and-assessing-pesticide-risks/standard-operating-procedures-residential-pesticide.
4. Cumulative effects from substances with a common mechanism of
toxicity. Section 408(b)(2)(D)(v) of FFDCA requires that, when
considering whether to establish, modify, or revoke a tolerance, the
Agency consider ``available information'' concerning the cumulative
effects of a particular pesticide's residues and ``other substances
that have a common mechanism of toxicity.''
Unlike other pesticides for which EPA has followed a cumulative
risk approach based on a common mechanism of toxicity, EPA has not made
a common mechanism of toxicity finding as to difenoconazole and any
other substances, although EPA has previously concluded that there are
no conclusive data that difenoconazole shares a common mechanism of
toxicity with other conazole pesticides. Although the conazole
fungicides (triazoles) produce 1,2,4 triazole and its acid-conjugated
metabolites (triazolylalanine and triazolylacetic acid), 1,2,4 triazole
and its acid-conjugated metabolites do not contribute to the toxicity
of the parent conazole fungicides (triazoles). A separate aggregate
risk assessment was conducted for triazole and the conjugated triazole
metabolites (Common Triazole Metabolites: Updated Aggregate Human
Health Risk Assessment to Address New Section 3 Registrations For Use
of Difenoconazole and Mefentrifluconazole; DP451447, dated May 15,
2019) and it can be found at https://www.regulations.gov at docket ID
number EPA-HQ-OPP-2018-0002. These new uses of difenoconazole
considered with existing uses of triazole compounds do not result in a
risk of concern for 1,2,4-trizaole and its metabolites. Difenoconazole
does not appear to produce any other toxic metabolite produced by other
substances. For the purposes of this action, therefore, EPA has not
assumed that difenoconazole has a common mechanism of toxicity with
other substances. For information regarding EPA's efforts to determine
which chemicals have a common mechanism of toxicity and to evaluate the
cumulative effects of such chemicals, see EPA's website at https://www.epa.gov/pesticide-science-and-assessing-pesticide-risks/cumulative-assessment-risk-pesticides.
D. Safety Factor for Infants and Children
1. In general. Section 408(b)(2)(C) of FFDCA provides that EPA
shall apply an additional tenfold (10X) margin of safety for infants
and children in the case of threshold effects to account for prenatal
and postnatal toxicity and the completeness of the database on toxicity
and exposure unless EPA determines based on reliable data that a
different margin of safety will be safe for infants and children. This
additional margin of safety is commonly referred to as the FQPA Safety
Factor (SF). In applying this provision, EPA either retains the default
value of 10X, or uses a different additional safety factor when
reliable data available to EPA support the choice of a different
factor.
2. Prenatal and postnatal sensitivity. The available toxicity
studies indicated no increased quantitative susceptibility of rats or
rabbits from in utero or postnatal exposure to difenoconazole. In
prenatal developmental toxicity studies in rats and rabbits and in the
2-generation reproduction study in rats, fetal/offspring toxicity, when
observed, occurred at equivalent or higher doses than in the maternal/
parental animals. In rabbits there was qualitative susceptibility since
the developmental effects were more severe than the maternal effects
seen at the same dose; however, the selected POD is protective of this
effect. In a rat developmental toxicity study, developmental effects
were observed at doses higher than those which caused maternal
toxicity. Developmental effects in the rat included increased incidence
of ossification of the thoracic vertebrae and hyoid, decreased number
of sternal centers of ossification, increased number of ribs and
thoracic vertebrae, and decreased number of lumbar vertebrae. In the
rabbit study, developmental effects (increases in post-implantation
loss and resorptions and decreases in fetal body weight) were also seen
at maternally toxic (decreased body weight gain and food consumption)
doses. In the two-generation reproduction study in rats, toxicity to
the fetuses/offspring (reduction in the body weight of F1 male pups),
when observed, occurred at equivalent or higher doses than in the
maternal/parental animals (reductions in body weight gain).
3. Conclusion. EPA has determined that reliable data show the
safety of infants and children would be adequately protected if the
FQPA SF were reduced to 1X. That decision is based on the following
findings:
i. The toxicity database for difenoconazole is sufficient for a
full hazard evaluation and is considered adequate to evaluate risks to
infants and children.
ii. There are no clear signs indication that difenoconazole is a
neurotoxic chemical following acute, subchronic, or chronic dosing in
multiple species in the difenoconazole database. The effects observed
in acute and subchronic neurotoxicity studies are considered non-
adverse as they were transient in nature and were only observed in one
sex (males as reduced fore-limb grip strength with no histologic
findings) and the selected endpoints of toxicity for risk assessment
are protective of any potential neurotoxicity. There is no need for a
developmental neurotoxicity study or additional UFs to account for
neurotoxicity.
iii. There is no evidence that difenoconazole results in increased
quantitative susceptibility in in utero rats or rabbits in the prenatal
developmental studies or in young rats in the 2-generation reproduction
study. However, in the developmental toxicity study in rabbits,
developmental effects (increases in post-implantation loss and
resorptions and decreases in fetal body weight) were also seen at
maternally toxic doses (decreased body weight gain and food
consumption). Because these effects are more severe, qualitative
susceptibility is evident in the rabbit. The PODs selected to assess
dietary exposures are protective of these effects.
iv. There are no residual uncertainties identified in the exposure
databases. The dietary food exposure assessments were performed based
on tolerance-level residues and 100% CT for the acute assessment while
the chronic assessment used USDA Pesticide Data Program (PDP)
monitoring data, average field trial residues for some commodities,
tolerance level residues for remaining commodities, and average percent
crop treated for some commodities. These assumptions will not
underestimate dietary exposure to difenoconazole. EPA made conservative
(protective) assumptions in the ground and surface water modeling used
to assess exposure to difenoconazole in drinking water. EPA used
similarly conservative assumptions to assess post-application exposure
of children. These
[[Page 8452]]
assessments will not underestimate the exposure and risks posed by
difenoconazole.
E. Aggregate Risks and Determination of Safety
EPA determines whether acute and chronic dietary pesticide
exposures are safe by comparing aggregate exposure estimates to the
aPAD and cPAD. For linear cancer risks, EPA calculates the lifetime
probability of acquiring cancer given the estimated aggregate exposure.
Short-, intermediate-, and chronic-term risks are evaluated by
comparing the estimated aggregate food, water, and residential exposure
to the appropriate PODs to ensure that an adequate MOE exists.
1. Acute risk. Using the exposure assumptions discussed in this
unit for acute exposure, the acute dietary exposure from food and water
to difenoconazole will occupy 52% of the aPAD for all infants <1 year
old, the population group receiving the greatest exposure.
2. Chronic risk. Using the exposure assumptions described in this
unit for chronic exposure, EPA has concluded that chronic exposure to
difenoconazole from food and water will utilize 53% of the cPAD for all
infants <1 year old, the population group receiving the greatest
exposure. Based on the explanation in Unit III.C.3., regarding
residential use patterns, chronic residential exposure to residues of
difenoconazole is not expected.
3. Short-term risk. Short-term aggregate exposure takes into
account short-term residential exposure plus average exposure levels to
food and water (considered to be a background exposure level).
Difenoconazole is currently registered for uses that could result in
short-term residential exposure, and the Agency has determined that it
is appropriate to aggregate chronic exposure through food and water
with short-term residential exposures to difenoconazole.
Using the exposure assumptions described in this unit for short-
term exposures, EPA has concluded the combined short-term food, water,
and residential exposures result in aggregate MOEs of 180 for adults
and 240 for children 6 to <11 years old. Because EPA's level of concern
for difenoconazole is an MOE of 100 or below, these MOEs are not of
concern.
4. Intermediate-term risk. Intermediate-term aggregate exposure
takes into account intermediate-term residential exposure plus chronic
exposure to food and water (considered to be a background exposure
level). An intermediate-term adverse effect was identified; however,
difenoconazole is not registered for any use patterns that would result
in intermediate-term residential exposure. Intermediate-term risk is
assessed based on intermediate-term residential exposure plus chronic
dietary exposure. Because there is no intermediate-term residential
exposure and chronic dietary exposure has already been assessed under
the appropriately protective cPAD (which is at least as protective as
the POD used to assess intermediate-term risk), no further assessment
of intermediate-term risk is necessary, and EPA relies on the chronic
dietary risk assessment for evaluating intermediate-term risk for
difenoconazole.
5. Aggregate cancer risk for U.S. population. As discussed in Unit
III.A., EPA has determined that use of the chronic reference dose will
be protective of the potential for cancer risk. Because the chronic
exposure does not exceed the Agency's level of concern, EPA concludes
that exposure to difenoconazole would not pose an unacceptable cancer
risk.
6. Determination of safety. Based on these risk assessments, EPA
concludes that there is a reasonable certainty that no harm will result
to the general population, or to infants and children from aggregate
exposure to difenoconazole residues.
IV. Other Considerations
A. Analytical Enforcement Methodology
An adequate tolerance enforcement method, gas chromatography with
nitrogen-phosphorus detection (GC/NPD) method AG-575B, is available for
the determination of residues of difenoconazole in/on plant
commodities. An adequate enforcement method, gas chromatography with
mass spectrometry detection (GC/MSD) method AG-676A, is also available
for the determination of residues of difenoconazole per se in/on canola
and barley commodities. A confirmatory method, GC/MSD method AG-676, is
also available.
An adequate tolerance enforcement method, Method REM 147.07b, is
available for livestock commodities. The method determines residues of
difenoconazole and CGA-205375 in livestock commodities by liquid
chromatography with tandem mass spectrometry detection (LC-MS/MS).
Adequate confirmatory methods, Method AG-544A and Method REM 147.06,
are available for the determination of residues of difenoconazole and
CGA-205375, respectively, in livestock commodities.
The method may be requested from: Chief, Analytical Chemistry
Branch, Environmental Science Center, 701 Mapes Rd., Ft. Meade, MD
20755-5350; telephone number: (410) 305-2905; email address:
[email protected].
B. International Residue Limits
In making its tolerance decisions, EPA seeks to harmonize U.S.
tolerances with international standards whenever possible, consistent
with U.S. food safety standards and agricultural practices. EPA
considers the international maximum residue limits (MRLs) established
by the Codex Alimentarius Commission (Codex), as required by FFDCA
section 408(b)(4). The Codex Alimentarius is a joint United Nations
Food and Agriculture Organization/World Health Organization food
standards program, and it is recognized as an international food safety
standards-setting organization in trade agreements to which the United
States is a party. EPA may establish a tolerance that is different from
a Codex MRL; however, FFDCA section 408(b)(4) requires that EPA explain
the reasons for departing from the Codex level.
Codex has established MRLs for difenoconazole in or on carrot at
0.2 ppm; edible offal at 1.5 ppm; sugar beet at 0.2 ppm; ginseng at
0.08 ppm; ginseng, dried at 0.8 ppm; and ginseng, extracts at 0.6 ppm.
Several of these MRLs are different than the tolerances established for
difenoconazole in the United States. The U.S. tolerance in/on crop
subgroup 1A, except ginseng (0.6 ppm), being established in this
rulemaking, is based on radish root data and cannot be harmonized with
the Codex MRL for carrot, which is lower than the subgroup tolerance;
doing so could result in exceedances of the tolerances even when
growers followed label directions. The U.S. tolerance for ginseng has
been harmonized with the Codex MRL for ginseng, dried and is inclusive
of the lower tolerances for ginseng and ginseng, extracts. The
tolerances for cattle, liver; goat, liver; horse, liver; and sheep,
liver cannot be harmonized with Codex MRLs due to different dietary
burdens.
C. Response to Comments
EPA received one comment opposing pesticide residues in food,
although no substantive information was provided for EPA to take into
consideration in its safety assessment. Although the commenter
generally expressed concern about the potential for exposure to
difenoconazole to be carcinogenic, EPA has evaluated the available data
on
[[Page 8453]]
carcinogenicity and exposure and determined that aggregate exposure to
difenoconazole will not cause a cancer risk. The FFDCA authorizes EPA
to establish tolerances that permit certain levels of pesticide
residues in or on food when the Agency can determine that such residues
are safe. EPA has made that determination for the tolerances subject to
this action; the commenter provided no information relevant to that
conclusion.
D. Revisions to Petitioned-For Tolerances
The terms ``tea;'' ``root vegetable crop subgroup 1A;'' ``leaves of
root and tuber vegetables crop group 2'' requested in the petition are
being replaced with ``tea, dried;'' ``vegetable, root, subgroup 1A,
except ginseng;'' and ``vegetable, leaves of root and tuber, group 2'',
respectively, to reflect the correct commodity definitions. The EPA has
modified the tolerance on tea, dried from the requested 30 ppm to 15
ppm to harmonize with Japan's draft MRL. The ginseng tolerance has been
removed from the vegetable, root, subgroup 1A and set at 0.8 to
harmonize with the highest Codex MRL. Tolerances for cattle, liver;
goat, liver; horse, liver; and sheep, liver have been increased from
0.40 to 0.7 ppm based on the re-calculated dairy cattle dietary burden
and the available feeding study data for residues of difenoconazole and
its metabolite CGA-205375. Trailing zeroes have been removed from
tolerances in accordance with current Agency practices.
E. International Trade Considerations
In this final rule, EPA is reducing the existing tolerance for
ginseng from 1.0 ppm to 0.8 ppm in order to harmonize with the Codex
MRL. Available residue data demonstrates that the new tolerance is
sufficient to cover residues on ginseng.
In accordance with the World Trade Organization's (WTO) Sanitary
and Phytosanitary Measures (SPS) Agreement, EPA intends to notify the
WTO of this revision in order to satisfy its obligation. In addition,
the SPS Agreement requires that Members provide a ``reasonable
interval'' between the publication of a regulation subject to the
Agreement and its entry into force to allow time for producers in
exporting Member countries to adapt to the new requirement. At this
time, EPA is establishing an expiration date for the existing ginseng
tolerance to allow that tolerance to remain in effect for a period of
six months after the effective date of this final rule, in order to
address this requirement. After the six month period expires, residues
of difenoconazole on ginseng cannot exceed the new tolerance of 0.8
ppm.
This reduction in tolerance levels is not discriminatory; the same
food safety standard contained in the FFDCA applies equally to
domestically produced and imported foods. The new tolerance levels are
supported by available residue data.
V. Conclusion
Therefore, tolerances are established for residues of
difenoconazole, difenoconazole, in or on vegetable, root, subgroup 1A,
except ginseng at 0.6ppm; vegetable, leaves of root and tuber, group 2
at 8 ppm; and tea, dried at 15 ppm. Tolerances are amended for ginseng
from 1.0 to 0.8 ppm; and cattle, liver; goat, liver; horse, liver; and
sheep, liver from 0.40 ppm to 0.7 ppm. In addition, the Agency is
removing the existing tolerances for beet, sugar; and carrot as they
are unnecessary upon the establishment of the tolerance for vegetable,
root, subgroup 1A, except ginseng. Finally, the Agency is amending the
existing tolerance for ginseng by adding an expiration date.
VI. Statutory and Executive Order Reviews
This action establishes tolerances under FFDCA section 408(d) in
response to a petition submitted to the Agency. The Office of
Management and Budget (OMB) has exempted these types of actions from
review under Executive Order 12866, entitled ``Regulatory Planning and
Review'' (58 FR 51735, October 4, 1993). Because this action has been
exempted from review under Executive Order 12866, this action is not
subject to Executive Order 13211, entitled ``Actions Concerning
Regulations That Significantly Affect Energy Supply, Distribution, or
Use'' (66 FR 28355, May 22, 2001) or Executive Order 13045, entitled
``Protection of Children from Environmental Health Risks and Safety
Risks'' (62 FR 19885, April 23, 1997), nor is it considered a
regulatory action under Executive Order 13771, entitled ``Reducing
Regulations and Controlling Regulatory Costs'' (82 FR 9339, February 3,
2017). This action does not contain any information collections subject
to OMB approval under the Paperwork Reduction Act (PRA) (44 U.S.C. 3501
et seq.), nor does it require any special considerations under
Executive Order 12898, entitled ``Federal Actions to Address
Environmental Justice in Minority Populations and Low-Income
Populations'' (59 FR 7629, February 16, 1994).
Since tolerances and exemptions that are established on the basis
of a petition under FFDCA section 408(d), such as the tolerance in this
final rule, do not require the issuance of a proposed rule, the
requirements of the Regulatory Flexibility Act (RFA) (5 U.S.C. 601 et
seq.), do not apply.
This action directly regulates growers, food processors, food
handlers, and food retailers, not States or tribes, nor does this
action alter the relationships or distribution of power and
responsibilities established by Congress in the preemption provisions
of FFDCA section 408(n)(4). As such, the Agency has determined that
this action will not have a substantial direct effect on States or
tribal governments, on the relationship between the National Government
and the States or tribal governments, or on the distribution of power
and responsibilities among the various levels of government or between
the Federal Government and Indian tribes. Thus, the Agency has
determined that Executive Order 13132, entitled ``Federalism'' (64 FR
43255, August 10, 1999) and Executive Order 13175, entitled
``Consultation and Coordination with Indian Tribal Governments'' (65 FR
67249, November 9, 2000) do not apply to this action. In addition, this
action does not impose any enforceable duty or contain any unfunded
mandate as described under Title II of the Unfunded Mandates Reform Act
(UMRA) (2 U.S.C. 1501 et seq.).
This action does not involve any technical standards that would
require Agency consideration of voluntary consensus standards pursuant
to section 12(d) of the National Technology Transfer and Advancement
Act (NTTAA) (15 U.S.C. 272 note).
VII. Congressional Review Act
Pursuant to the Congressional Review Act (5 U.S.C. 801 et seq.),
EPA will submit a report containing this rule and other required
information to the U.S. Senate, the U.S. House of Representatives, and
the Comptroller General of the United States prior to publication of
the rule in the Federal Register. This action is not a ``major rule''
as defined by 5 U.S.C. 804(2).
List of Subjects in 40 CFR Part 180
Environmental protection, Administrative practice and procedure,
Agricultural commodities, Pesticides and pests, Reporting and
recordkeeping requirements.
[[Page 8454]]
Dated: December 19, 2019.
Michael Goodis,
Director, Registration Division, Office of Pesticide Programs.
Therefore, 40 CFR chapter I is amended as follows:
PART 180--[AMENDED]
0
1. The authority citation for part 180 continues to read as follows:
Authority: 21 U.S.C. 321(q), 346a and 371.
0
2. In Sec. 180.475:
0
a. In the table in paragraph (a)(1):
0
i. Remove the entries ``Beet, sugar'' and ``Carrot''.
0
ii. Revise the entry for ``Ginseng''.
0
iii. Add a second entry for ``Ginseng'' after the existing entry for
``Ginseng'' and add alphabetically the entries ``Tea, dried'';
``Vegetable, leaves of root and tuber, group 2''; and ``Vegetable,
root, subgroup 1A, except ginseng''.
0
iv. Add footnotes 1 and 2 to the end of the table.
0
b. Revise the entries ``Cattle, liver''; ``Goat, liver''; ``Horse,
liver''; and ``Sheep, liver'' in the table in paragraph (a)(2).
The additions and revisions read as follows:
Sec. 180.475 Difenoconazole; tolerances for residues.
(a) * * *
(1) * * *
------------------------------------------------------------------------
Parts per
Commodity million
------------------------------------------------------------------------
* * * * *
Ginseng \2\................................................. 1.0
Ginseng..................................................... 0.8
* * * * *
Tea, dried \1\.............................................. 15
* * * * *
Vegetable, leaves of root and tuber, group 2................ 8
Vegetable, root, subgroup 1A, except ginseng................ 0.6
* * * * *
------------------------------------------------------------------------
\1\ There are no U.S. registrations for these commodities.
\2\ This tolerance expires on August 14, 2020.
(2) * * *
------------------------------------------------------------------------
Parts per
Commodity million
------------------------------------------------------------------------
* * * * *
Cattle, liver............................................... 0.7
* * * * *
Goat, liver................................................. 0.7
* * * * *
Horse, liver................................................ 0.7
* * * * *
Sheep, liver................................................ 0.7
* * * * *
------------------------------------------------------------------------
* * * * *
[FR Doc. 2020-02241 Filed 2-13-20; 8:45 am]
BILLING CODE 6560-50-P